Cronos Group Inc. (CRON) stock
CRONNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 15/3010% below fair value
$3.19−0.08 (-2.45%)
Close on Nov 17, 2026Market cap $1.18BP/E 15.9Yield –
Cronos price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Cronos's price to sales ratio was 7.1× on Nov 11, 2026, against 7.1× a year earlier. Over the last 5 years it ranged from 5.9× to 22.6×, with a median of 8.5×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 7.1× | −0.5 |
| 2025 | Dec 31, 2025 | 7.6× | +0.7 |
| 2024 | Dec 31, 2024 | 6.9× | −2.4 |
| 2023 | Dec 29, 2023 | 9.3× | −2.3 |
| 2022 | Dec 30, 2022 | 11.6× | −10.7 |
| 2021 | Dec 31, 2021 | 22.3× | −46.6 |
| 2020 | Dec 31, 2020 | 68.9× | −348.0 |
| 2018 | Oct 31, 2018 | 416.8× | – |
See a number that looks wrong?